


**Supplemental Figure 1. Linkage disequilibrium structure of the *LPL* gene on chromosome 8 in the study population**



**Supplemental Table 1: ANOVA for baseline HDL-C and TG levels across genotypes for the FA–statin combination therapy group**

<b>SNP</b>	<b>Homozygous</b>	<b>Heterozygous</b>	<b>Wild-type</b>	<b>P*</b>
<b>rs1801177</b>	<b>A/A</b>	<b>G/A</b>	<b>G/G</b>	
Mean TG (mg/dL)	NI	235	286	<b>0.18</b>
Mean HDL-C (mg/dL)	NI	37.8	38.2	<b>0.8</b>
<b>rs7016529</b>	<b>G/G</b>	<b>G/A</b>	<b>A/A</b>	
Mean TG (mg/dL)	NI	239	285	<b>0.45</b>
Mean HDL-C (mg/dL)	NI	37.6	38.2	<b>0.3</b>
<b>rs249</b>	<b>G/G</b>	<b>G/A</b>	<b>A/A</b>	
Mean TG (mg/dL)	NI	273	286	<b>0.53</b>
Mean HDL-C (mg/dL)	NI	38.2	38.2	<b>0.98</b>

\* Multiway ANOVA

NI, none identified in the study

**Supplemental Table 2: Association analyses for SNPs rs1801177, rs7016529, and rs249 in the FA–statin combination treatment group for percent change in HDL-C and TG using multivariate regression adjusted for age, sex, body mass index, smoking, baseline trait level, baseline TG level (for HDL-C), and diabetes status**

Gene	SNP	MAF	Minor allele	HDL-C		TG	
				P	Beta	P	Beta
<i>LPL</i>	rs1801177	2.0%	A	0.29	−3.73	0.51	2.8
<i>LPL</i>	rs7016529	2.1%	G	0.41	−2.80	0.42	3.4
<i>LPL</i>	rs249	7.5%	G	0.12	−3.12	0.002	7.5

Based on NCBI Build 36.1; beta, beta coefficient; FA, fenofibric acid; MAF, minor allele frequency

**Supplemental Table 3: ANOVA for the mean percent change in HDL-C and TG across genotypes in the FA–statin combination therapy group**

<b>SNP</b>	<b>Homozygous</b>	<b>Heterozygous</b>	<b>Wild-type</b>	<b>P*</b>
<b>rs1801177</b>	<b>A/A</b>	<b>G/A</b>	<b>G/G</b>	
Mean TG change (%)	NI	-32.9	-45.4	<b>0.06</b>
Mean change HDL-C (%)	NI	22	25.7	<b>0.06</b>
<b>rs7016529</b>	<b>G/G</b>	<b>G/A</b>	<b>A/A</b>	
Mean change TG (%)	NI	-34.4	-45.3	<b>0.2</b>
Mean change HDL-C (%)	NI	20.5	21.5	<b>0.15</b>
<b>rs249</b>	<b>G/G</b>	<b>G/A</b>	<b>A/A</b>	
Mean change TG (%)	NI	-34.0	-46.9	<b>0.0004</b>
Mean change HDL-C (%)	NI	19.6	21.8	<b>0.09</b>

\* Multiway ANOVA

NI, none identified in the study

**Supplemental Table 4: Haplotypes composed of SNPs rs1801177, rs7016529, and rs249 and their associations with baseline HDL-C and TG levels in the group receiving FA-statin combination therapy, adjusted for age, sex, body mass index, smoking, and diabetes status**

Haplotype	Frequency	HDL-C		TG	
		Beta coefficient	P for baseline level	Beta coefficient	P for baseline level
AGG	0.02	0.16	0.9	-21.6	0.44
GAG	0.06	0.08	0.9	-4.7	0.78
GAA	0.92	0.10	0.9	9.7	0.50

**Supplemental Table 5: Haplotypes composed of SNPs rs1801177, rs7016529, and rs249 and their associations with response of HDL-C and TG to FA–statin combination therapy, adjusted for age, sex, body mass index, smoking, and diabetes status**

Haplotype	Frequency	HDL-C		TG	
		Beta	P for percent	Beta	P for percent
		coefficient	change	coefficient	change
AGG	0.02	-3.9	0.30	3.82	0.42
GAG	0.06	-2.7	0.25	8.10	0.005
GAA	0.92	2.9	0.15	-6.93	0.004